1/37
Looks like no tags are added yet.
Primary therapeutic purpose of muscarinic cholinergic antagonists in airway disease
Prevent bronchoconstriction and mucus production by blocking acetylcholine on airway muscarinic receptors
Diseases treated with antimuscarinics
Asthma and COPD, more commonly COPD
Mechanism by which antimuscarinic drugs improve airflow
Compete with acetylcholine at muscarinic receptors, reducing parasympathetic-mediated airway narrowing
Examples of antimuscarinic agents used in airway disease
Ipratropium, tiotropium, umeclidinium
Role of LAMAs in asthma therapy
Used in combination with inhaled corticosteroids for chronic control
Common systemic adverse effects of antimuscarinic therapy
Dry mouth, blurred vision, constipation, urinary retention, confusion
Cause of bad taste particularly with ipratropium
Local effect in oropharynx
Reason nebulized antimuscarinics may worsen glaucoma
Drug can reach ocular tissue during nebulization
Primary PDE4 inhibitor used for COPD
Roflumilast
Indication of PDE4 inhibitors
Severe COPD with history of exacerbations (not for acute bronchospasm)
Clinical benefit of dual PDE3/4 inhibition
Additive anti‑inflammatory and bronchodilatory effects
Mechanistic result of PDE4 inhibition in airways
Increased cAMP, reduced inflammatory cells and cytokines, decreased bronchoconstriction
Common side effects of PDE4 inhibitors
Diarrhea, weight loss, nausea, headache in 5‑10% of patients
Pharmacokinetic features of PDE4 inhibitor
Oral bioavailability ~80%; active metabolite; metabolized by CYP1A2 and CYP3A4
Important drug interactions with PDE4 inhibitors
Rifampin induces metabolism; ketoconazole and erythromycin inhibit metabolism
PDE4 inhibitor contraindication
Moderate or severe hepatic impairment (Child‑Pugh B or C)
Therapeutic purpose of leukotriene modifiers
Manage chronic asthma by targeting leukotriene‑mediated inflammation and bronchoconstriction
Administration route of leukotriene modifiers
Oral
Drug that inhibits 5‑lipoxygenase
Zileuton
Drugs that block leukotriene receptors
Montelukast, pranlukast, zafirlukast
Physiologic result of leukotriene receptor antagonism
Reduced bronchoconstriction, fewer eosinophils recruited, decreased mucus secretion
Metabolic pathways relevant to montelukast
Substrate of CYP3A4 and CYP2C9
Reported side effects of leukotriene modifiers
Headache, nausea, abdominal pain, cough; possible liver enzyme elevation
Black box warning associated with leukotriene modifiers
Neuropsychiatric reactions reported in 2020, not for zafirlukast
Mechanism of omalizumab
Binds IgE, prevents mast cell activation and allergic inflammatory cascade
Clinical use of omalizumab
Severe allergic asthma
Administration of omalizumab
Subcutaneous every 2-4 weeks
Dependence of omalizumab dosing
Body weight and IgE level
Examples of anti‑IL‑5 monoclonal antibodies
Mepolizumab and reslizumab
Benralizumab mechanism
Binds IL‑5 receptor
Dupilumab mechanism
Binds IL‑4 receptor
Common requirement for monoclonal antibody administration
Must be given in a setting equipped to manage anaphylaxis
Important precaution when starting monoclonal antibody therapy
Do not abruptly discontinue inhaled corticosteroids
Reported side effects of monoclonal antibodies
Arthralgia, fatigue, dizziness, pruritus, dermatitis, injection‑site reactions, rare anaphylaxis
Purpose of ICS + LABA combinations
Complementary short‑term and long‑term control of airway inflammation and bronchoconstriction
Examples of ICS + LABA combinations
Budesonide + formoterol, fluticasone propionate + salmeterol, fluticasone furoate + vilanterol
Purpose of LAMA + LABA combinations in COPD
Dual bronchodilation by muscarinic blockade and β2 stimulation
Examples of triple therapy components
Corticosteroid, long‑acting muscarinic antagonist, and long‑acting β2‑agonist